Related by context. All words. (Click for frequent words.) 68 placebo controlled Phase III 68 dosing cohorts 67 Diabetic Macular Edema 66 placebo controlled Phase 66 double blinded placebo 65 HCV SPRINT 65 symptomatic BPH 64 LUMINATE 64 RE LY ® 64 NATRECOR R 64 HCV RESPOND 2 64 AIR CF1 64 dose cohort 64 placebo intravenously 64 Phase IIIb clinical 64 phase IIb trial 63 RAPTIVA 63 multicenter Phase III 63 active comparator 63 phase IIb clinical 63 interferon gamma 1b 63 dose cohorts 63 INCB# [003] 63 Phase IIIb 63 placebo controlled clinical 63 GAMMAGARD 63 AVOREN 62 CLARITY study 62 relapsed refractory multiple myeloma 62 blinded randomized placebo controlled 62 Phase Ib study 62 oral deforolimus 62 STRIDE PD 62 BLA submission 62 metastatic hormone refractory 62 ROCKET AF 62 mg administered orally 62 telaprevir dosing 62 ascending dose 62 Phase Ib clinical 62 standard chemotherapy regimen 62 μg dose 62 TACI Ig 62 dosing cohort 62 COMFORT II 62 Phase IIIb study 62 Raptiva R 62 placebo controlled clinical trials 62 RSD# oral 62 GSK# [001] 62 PEGINTRON TM 61 CIMZIA TM 61 SAR# [004] 61 Traficet EN 61 APTIVUS r 61 FOLOTYN ® 61 Phase IIa trial 61 bepotastine besilate nasal spray 61 severe hypercholesterolemia 61 BR.# 61 YONDELIS 61 ARCOXIA 61 TG MV 61 comparator arm 61 primary hypercholesterolemia 61 Pivotal Trial 61 evaluable subjects 61 Phase III Clinical Trials 61 Phase Ib II 61 retrospective cohort 61 randomized controlled Phase 61 tacrolimus ointment 61 controlled multicenter 61 R# #mg BID 61 RELOVAIR ™ 61 Xelox 61 trastuzumab emtansine T DM1 61 CAMMS# 61 MIVI III 61 Tezampanel 61 NSABP B 61 multicenter placebo controlled 61 ruboxistaurin 61 Ozarelix 60 Tarceva TM 60 alvimopan 60 Folfox 60 ALGRX 60 PSMA ADC 60 ongoing Phase 1b 60 Sapacitabine 60 sNDA submission 60 multicenter multinational 60 refractory chronic lymphocytic 60 ORENCIA ® 60 TMC# C# 60 PRECiSE 60 Amrubicin 60 oral ridaforolimus 60 multicenter randomized double 60 Phase Ib 60 ALN HPN 60 albinterferon alfa 2b 60 CHAMPION PCI 60 Prospective Randomized 60 oral rivaroxaban 60 liver transplantations 60 null responder HCV 60 EURIDIS 60 ENDEAVOR IV 60 NVA# 60 cell lymphoma CTCL 60 Pivotal Clinical Trial 60 PROMACTA 60 pralatrexate injection 60 Acute myeloid leukemia AML 60 DASISION 60 ENDEAVOR II 60 EQUATE OB 60 LIALDA 60 Pirfenidone 60 phase Ib clinical 60 muraglitazar 60 Raptiva ® 60 insulin detemir 60 huC# DM4 60 TAXUS IV 60 phase IIb 60 ROTATEQ 60 ECASS 60 stage IIIB 60 BCIRG 60 ADVANCE PD 60 mapatumumab 60 rosuvastatin #mg 60 Engerix B 60 MAA submission 60 AIR2 Trial 60 COPEGUS 60 Elitek 60 mertansine 60 MAGE A3 ASCI 60 MEND CABG 60 thymalfasin 60 Jevtana 59 CYPHER Stent 59 #mg q8h 59 PEGASYS ® 59 Phase III Pivotal 59 relapsed MM 59 pegylated interferon alfa 2a 59 APTIVUS 59 posaconazole 59 Cimzia ® certolizumab pegol 59 EDEMA3 59 mg q8h 59 Pivotal Phase III 59 trials RCTs 59 mixed dyslipidemia 59 treatment naive genotype 59 Golimumab 59 prospective multicenter 59 GW# [003] 59 QD dosing 59 prospective randomized multicenter 59 lixisenatide 59 crizotinib PF # 59 REVLIMID lenalidomide 59 sunitinib malate 59 Iluvien 59 Renal Cell Carcinoma RCC 59 randomized multicenter 59 Azedra 59 Brentuximab Vedotin SGN 59 oral diclofenac 59 Alocrest 59 CIMZIA ™ 59 Carotid Revascularization Endarterectomy vs. 59 BRIM2 59 dose escalation trial 59 Diabetic Macular Edema DME 59 mcg QD 59 low dose cytarabine 59 multicenter Phase II 59 brivaracetam 59 MGd 59 TYGACIL 59 cediranib 59 Pegasys ® 59 GetGoal Phase III 59 PREZISTA r 59 telaprevir dosed 59 docetaxel Taxotere ® 59 evaluating REVLIMID 59 CIMZIA TM certolizumab pegol 59 Phase 1b trial 59 Phase 1b 59 Aryplase 59 dose escalation phase 59 pegylated interferon alfa 2b 59 Phase IIa trials 59 evaluating tivozanib 59 budesonide foam 59 heFH 59 INCB# [001] 59 efalizumab 59 Phase 2b trial 59 Phase III Clinical Trial 59 Cutaneous T 59 EQUIP OB 59 tolvaptan 59 Prostate AdenoCarcinoma Treatment 59 ONGLYZA 59 MoxDuo IR 59 hepatitis C HCV 59 TMC# r 59 phase IIb study 59 Phase #b/#a 59 ritonavir boosted atazanavir 59 Myocardial Infarction Study 59 riociguat 59 dacarbazine 59 intravitreal insert 59 MERLIN TIMI 59 CINTREDEKIN BESUDOTOX 59 Neulasta R 59 phase Ib 59 rilpivirine 59 elotuzumab 59 Advanced Renal Cell 59 ularitide 59 phase III isavuconazole 59 CANCIDAS 59 PARTNER Trial 58 IV bolus 58 ARIXTRA 58 EchoCRT 58 oral FTY# 58 sorafenib tablets 58 Gemzar ® 58 ug dose 58 Dacogen injection 58 LUX Lung 58 Phase 2b study 58 HCV protease inhibitor 58 INSPIRE Trial Phase III 58 Vicinium TM 58 TORISEL 58 lopinavir r arm 58 alemtuzumab treated 58 Onrigin 58 blind randomized placebo 58 Ranolazine 58 KRAS mutations occur 58 Phase 2a trial 58 ritonavir boosted 58 8mg/kg 58 CTAP# Capsules 58 carboplatin paclitaxel 58 Zenvia Phase III 58 Diamyd ® 58 irbesartan 58 clinical pharmacology studies 58 nab paclitaxel 58 phase IIa clinical 58 LEXIVA r 58 dose escalation Phase 58 randomized Phase III 58 pharmacokinetic PK study 58 huN# DM1 58 Phase III psoriasis 58 Augment Injectable 58 atazanavir ritonavir 58 multicenter Phase 58 ibandronate 58 mcg albinterferon alfa 2b 58 Screening Trial 58 #mg/m# [001] 58 CR# vcMMAE 58 mGluR5 negative 58 diabetic neuropathic pain 58 Aflibercept 58 placebo controlled studies 58 mg BID dose 58 Betaferon ® 58 XIENCE V Stent System 58 evaluating mipomersen 58 fenofibric acid 58 COPAXONE ® 58 #mg doses [002] 58 oxycodone CR 58 RECORD1 58 Onrigin TM 58 registrational 58 NEVO 58 BAY #-# 58 Safinamide 58 BRIM3 58 Aurexis 58 dosage regimens 58 AGILECT R 58 placebo controlled 58 prospective randomized placebo 58 HBeAg negative 58 Cladribine Tablets 58 Velcade bortezomib 58 non squamous NSCLC 58 Dapagliflozin 58 TEAEs 58 cisplatin vinorelbine 58 ascending doses 58 Endeavor Resolute DES 58 Bronchitol 58 certolizumab 58 ZOMIG R 58 Taxotere ® 58 RE LY 58 retinal vein occlusion 58 Phase IIb clinical trials 58 p# biomarker 58 refractory CLL 58 PDX pralatrexate 58 phase IIa 58 Eraxis 58 postmenopausal osteoporotic women 58 multicenter phase 58 Phase 2b Clinical Trial 58 acyclovir Lauriad R 58 lorcaserin Phase 58 q#h 58 COPAXONE R 58 multicenter randomized controlled 58 Gabapentin GR 58 recurrent glioblastoma multiforme 58 Zytiga 58 Dupuytren Contracture 58 T Pred 58 novel VDA molecule 58 adult chronic ITP 58 oral iron chelator 58 PROPEL trial 58 OPT CHF 58 Sorafenib HCC Assessment 58 Quinamed 58 multicentre randomized 58 Systemic Sclerosis 58 PEG INTRON 58 ENESTnd 58 abiraterone acetate 58 PD LID 58 MoxDuo TM IR 58 Acute Decompensated Heart Failure 58 fluvastatin 58 Acute Ischemic Stroke 58 GTC recombinant human 58 INTEGRILIN 58 EOquin TM 58 achieved ACR# 58 treatment naïve genotype 58 rilonacept 58 dyskinesia PD LID 58 SNT MC# 58 ziprasidone Geodon 58 Dalbavancin 58 Thrombolysis 58 blinded placebo controlled 58 Tekamlo 58 pharmacokinetic PK 57 ceftazidime 57 plus Copegus R 57 tasocitinib 57 Virulizin R 57 plus methotrexate 57 PERSEUS 57 Elagolix 57 JANUVIA 57 multicenter randomized placebo controlled 57 mg q#h 57 Hycamtin ® 57 de novo kidney transplant 57 SCIg 57 recurrent NSCLC 57 Complete Response 57 Degarelix 57 cIAI 57 Fibrillex TM 57 vicriviroc 57 Pivotal Phase 57 inhibitor RG# 57 peginterferon alfa 2a 57 relapsing remitting MS RRMS 57 lexidronam injection 57 IL# PE#QQR 57 LEUKINE 57 perifosine KRX 57 rheumatoid arthritis psoriatic arthritis 57 dose escalation study 57 AzaSite Plus 57 prospective multicenter randomized 57 AIR CF2 57 dose escalation 57 YERVOY 57 Lubiprostone 57 rotigotine 57 peg IFN 57 TASKi2 57 Hemopurifier ® treatments 57 relapsed multiple myeloma 57 intradermal injections 57 RRMS patients 57 tgAAC# 57 Albuferon TM 57 Afatinib 57 Betaferon R 57 Marketing Authorization Application 57 homozygous familial hypercholesterolemia 57 galiximab 57 docetaxel Taxotere R 57 chronic HCV infection 57 REBETOL combination therapy 57 randomized controlled multicenter 57 Peg IFN 57 #mg dosing group 57 Glufosfamide 57 tramiprosate Alzhemed TM 57 pulmonology portfolio 57 metformin HCl 57 prospectively defined 57 intravitreal injection 57 4mg/kg 57 hyperphenylalaninemia HPA due 57 desvenlafaxine succinate 57 melphalan prednisone 57 mg BID 57 Phase 2b monotherapy 57 #mg BID [003] 57 FDA Investigational Device 57 NATRECOR ® 57 Ganite R 57 AEG# 57 aflibercept 57 Cimzia TM 57 placebo controlled randomized 57 multicenter clinical 57 Phase 2a 57 rALLy trial 57 MYCAMINE 57 prucalopride 57 dacetuzumab SGN 57 refractory multiple myeloma 57 Solid Tumors 57 Hepatocellular Carcinoma HCC 57 arsenic trioxide injection 57 Plicera 57 secondary efficacy endpoints 57 REVLIMID R 57 Apaziquone 57 CALGB # [002] 57 saline placebo 57 candesartan cilexetil 57 Octreolin 57 Alinia 57 Allovectin 7 ® 57 Prostate Lung Colorectal 57 terlipressin 57 DSMB 57 BCR ABL inhibitor 57 underwent surgical resection 57 Phase III randomized 57 colesevelam HCl 57 randomized blinded 57 REYATAZ r 57 PEG INTRON R 57 STELARA TM 57 OvaRex ® MAb 57 PLCO 57 IMC A# 57 essential thrombocythemia 57 Randomized Phase II 57 composite endpoint 57 Investigational Device Exemption IDE 57 rapid virologic response 57 Aplidin R 57 HORIZONS AMI trial 57 acute coronary syndromes ACS 57 Cloretazine ® 57 Phase III randomized controlled 57 multicentre 57 Randomized Study 57 Medidur TM FA 57 methylnaltrexone 57 DU #b 57 AVADO 57 dirucotide 57 basal bolus regimen 57 Phase III pivotal 57 mg QD 57 relapsing multiple sclerosis 57 unfractionated heparin UFH 57 DAPT 57 NCCTG 57 pertuzumab 57 forodesine 57 Phase IIb Clinical Trial 57 Raptiva r 57 AeroLEF TM 57 alfa 2a 57 azathioprine monotherapy 57 FOLFIRI 57 Torisel 57 metastatic HRPC 57 ExTRACT TIMI 57 Phase III placebo controlled 57 pegylated interferon alpha 57 sitagliptin 57 RhuDex ® 57 cardio renal 57 TYKERB 57 midstage clinical 57 BARI 2D 57 LymphoStat B belimumab 57 constipation OIC 57 AVONEX ® 57 EGFR HER2 56 CALGB 56 ZEVALIN therapeutic regimen 56 dose escalation clinical 56 SUCCEED trial 56 FDA Approvable Letter 56 underwent resection 56 Matrix Phase 2b 56 dextromethorphan quinidine 56 recurrent GBM 56 Aloxi injection 56 DermaVir Patch 56 Dose Ranging Study 56 definite stent thrombosis 56 tesmilifene 56 hoFH 56 silodosin 56 mg/m2 dose 56 Hodgkin lymphoma HL 56 trastuzumab DM1 T DM1 56 Onco TCS 56 Randomized Evaluation 56 TAXUS Element Stent System 56 TAXUS ATLAS 56 ARCALYST ® 56 ALN TTR 56 Leukemias 56 GATTEX ® 56 unresectable HCC 56 Phase 1a clinical 56 rFVIIa 56 ACTEMRA TM 56 ARCALYST ® rilonacept 56 HoFH 56 Phase IIb Trial 56 Rebif ® 56 myelofibrosis polycythemia vera 56 Methylnaltrexone 56 Wafer polifeprosan 56 LUNESTA ® 56 CERVARIX 56 angiographic outcomes 56 ToGA 56 blind randomized 56 FOLPI 56 TBC# 56 trastuzumab Herceptin R 56 Oral Fingolimod 56 Cleviprex TM clevidipine 56 Cloretazine 56 complement inhibitor eculizumab 56 label dose escalation 56 afatinib 56 ancrod 56 Phase IIb trial 56 underwent CABG 56 Pivotal Study 56 Phase IIb III 56 antibody MAb 56 low dose Iluvien 56 Contrave# 56 NP2 Enkephalin 56 Phase 2a Clinical Trial 56 Phase 2b 56 dose dose escalation 56 ZACTIMA 56 idursulfase 56 acyclovir Lauriad ® 56 eosinophilic asthma 56 ABSORB trial 56 Eloxatin ® 56 lipid lowering agents 56 Triolex 56 BYETTA ® 56 Phase Ib clinical trials 56 IBS C 56 axitinib 56 mcg doses 56 Randomized Phase 56 Phase #b/#a clinical 56 ONGLYZA ™ 56 BioNumerik 56 Phase 1b clinical 56 pegylated liposomal doxorubicin 56 SYNTAX trial 56 teriflunomide 56 post herpetic neuralgia PHN 56 neratinib 56 SUTENT 56 HBeAg positive 56 Iluvien ® 56 rALLy clinical trial 56 HuMax EGFr 56 randomized Phase 56 alvespimycin 56 Ridaforolimus 56 timepoints 56 STELARA 56 phase IIIb 56 canakinumab 56 INVANZ 56 AZILECT ® 56 piperacillin tazobactam 56 double blinded randomized 56 NeuroStar TMS Therapy 56 Novartis MenB vaccine 56 lintuzumab SGN 56 Ixempra 56 mg kg dose 56 histologies 56 familial amyloidotic polyneuropathy FAP 56 QUADRAMET R 56 Panzem R 56 Gynecologic Oncology Group 56 MADIT II 56 RG# [001] 56 XIENCE V PROMUS Stent 56 Navelbine ® 56 MIRCERA 56 subanalysis 56 romidepsin 56 NOXAFIL 56 TEMODAL 56 Nexavar sorafenib 56 PREZISTA ritonavir 56 Laquinimod 56 ELND# 56 tapentadol ER 56 PegIntron 56 Fludara 56 MabCampath 56 TELCYTA 56 Phase 2b Study 56 ocular formulation 56 Anturol TM 56 Hepatocellular Carcinoma 56 AZILECT R 56 NEO3 56 stage IIIb IV 56 thorough QT 56 Phase III clinical 56 Controlled Trial 56 Phase #/#a trial 56 Nimotuzumab 56 Cethromycin 56 tocilizumab 56 ASPIRE HIGHER 56 ACTEMRA 56 postintervention 56 prospective multicenter study 56 ofatumumab HuMax CD# 56 phase III ACCLAIM 56 Myelodysplastic syndromes MDS 56 GEM OS1 56 APF# Phase 56 non alcoholic steatohepatitis 56 Dual Opioid 56 CUSTOM III 56 ACUITY trial 56 Ceflatonin ® 56 MKC# MKC# PP 56 sarcoma melanoma 56 blinded randomized 56 BYDUREON 56 PEG SN# 56 Phase 2a Trial 56 #mg BID [001] 56 placebo controlled trials 56 REVIVE Diabetes 56 SYMMETRY trial 56 Zenvia ™ 56 multicenter trials 56 RezularTM 56 Naive Patients 56 Tanespimycin 56 Bezielle 56 COU AA 56 metastatic neuroendocrine tumors 56 RANK Ligand inhibitor 56 randomized multicenter Phase III 56 Autologous Stem Cell Transplantation 56 Tumor Response 56 Phase IIB 56 metastatic castration resistant 56 Durezol TM 56 prospective observational cohort 56 Fibrin Pad 56 JAK inhibitor 56 EFAPROXYN 56 Zavesca R 56 DEB# 56 clevidipine 56 bevirimat Study 56 Efficacy Results 56 EmbraceAC 56 plus dexamethasone 56 registrational trial 56 Maximum Tolerated Dose MTD 56 mg RDEA# 56 ponatinib 56 double blind placebo 56 SPIRIT FIRST 56 RHUCIN 56 PEG Intron ® 56 Topline Results 56 Dose escalation 56 NUVIGIL 56 histone deacetylase HDAC inhibitor 56 invasive candidiasis 56 CCX# 56 SPRYCEL ® 56 ipsilateral stroke 56 SCH # 56 pramlintide 56 Heart Failure Trial 56 tenofovir emtricitabine 56 evaluating Xcytrin 56 Initiated Phase 56 receiving INTRON 56 lenalidomide dexamethasone 56 Phase IIb 56 ANCHOR trial 56 Zorbtive TM 56 samarium Sm 56 Prostate Cancer Prevention 56 Investigational Treatment 56 THALOMID 56 rFSH 56 Randomized Double blind 56 mcg BID 56 #mg QD [002] 56 ENGAGE AF TIMI 56 relapsed APL 56 NYHA Class II 56 ALN VSP Phase 56 Randomized Controlled 56 ATACAND 56 PEGylated interferon beta 1a 56 blind multicenter 56 MEK Inhibitor 56 mg Proellex 56 timepoint 56 Interagency Registry 56 Vicriviroc 56 Omacetaxine mepesuccinate 56 valopicitabine 56 FUSILEV ® 55 darapladib 55 Phase 1b clinical trials 55 Microplasmin 55 Proellex TM 55 Phase #/#a 55 Blinatumomab 55 refractory cutaneous T 55 tipranavir ritonavir 55 RE LY trial 55 PAOD 55 Genasense ® 55 Ocrelizumab 55 PRISTIQ 55 octreotide implant 55 glatiramer acetate 55 Daclizumab 55 Clinical Antipsychotic Trials 55 ribavirin RBV 55 BUPHENYL 55 ENDEAVOR III 55 TYZEKA 55 bicifadine 55 ISENTRESS 55 GEM OS2 55 toenail onychomycosis 55 EndoTAG TM -1 55 PROMUS Element Stent 55 dirucotide MBP# 55 Corlux 55 YONDELIS R 55 HGS# 55 OPAXIO 55 pitavastatin 55 omega interferon 55 danoprevir 55 ATL# [001] 55 interferon beta 1b 55 Combination REOLYSIN R 55 Study Evaluating 55 PROactive Study 55 CoFactor 55 ixabepilone 55 Fludara ® 55 leukemia AML 55 fosbretabulin 55 IV NSCLC 55 efavirenz EFV 55 KAPIDEX 55 Ceflatonin R 55 Phase Ia 55 intravenous dosing 55 risperidone olanzapine 55 Epratuzumab 55 Vernakalant 55 apaziquone 55 Liver biopsies 55 mcg kg 55 Tamibarotene 55 HPTN 55 nitric oxide donating prostaglandin 55 TAXUS Express Stent 55 Phase III clinical trials 55 ezogabine 55 painful diabetic neuropathy 55 ALVESCO 55 TAXUS TM 55 atrasentan 55 advanced metastatic prostate 55 mg doses 55 PROSTVAC TM 55 IMiDs ® compound 55 everolimus eluting stents 55 Phenoptin 55 Pegasys plus Copegus 55 APEX AMI trial 55 ZOSTAVAX 55 DAPT Study 55 alemtuzumab Campath 55 pivotal Phase III 55 fluticasone furoate 55 Drug Eluting Stent System 55 flutamide 55 Xcellerated T Cells 55 q8h 55 dabigatran etexilate 55 paclitaxel eluting stents 55 icatibant 55 NDA Submission 55 Mipomersen 55 Edurant 55 NOX E# 55 Diovan Exforge Tekturna Zelnorm 55 enzastaurin 55 metastatic castrate resistant 55 investigational protease inhibitor 55 CRESTOR #mg 55 randomized placebo controlled 55 Teriflunomide 55 vinorelbine tartrate 55 Neulasta ® 55 AVE# 55 dose regimens 55 viral kinetic 55 Reverset 55 TRISENOX ® 55 achieved statistical significance 55 patients evaluable 55 intravesical infusion therapy 55 Lymphocytic 55 R bendamustine hydrochloride 55 Phase 2b clinical 55 refractory APL 55 prospective observational 55 PRIMO CABG 55 Phase 1b dose escalation 55 Palifosfamide 55 label multicenter 55 Forodesine HCl 55 Monitoring ABPM 55 Tekturna HCT 55 virus HCV infection 55 Iloperidone 55 GATTEX TM 55 Platelet Inhibition 55 GABITRIL 55 TMC# [002] 55 dose titration 55 PROSTASCINT R 55 Zolinza 55 nasal calcitonin product 55 Solazed TM 55 ORMD 55 INTEGRILIN R 55 FIRAZYR 55 Patient Outcomes 55 edoxaban 55 PRESEPT 55 ThermoDox R 55 HDAC Inhibitor 55 BRILINTA 55 Severe Sepsis 55 docetaxel prednisone 55 CD# monoclonal antibody 55 IFN alfa 55 Lung Rx 55 FOLFOX6 chemotherapy regimen 55 AEGR 55 PEARL SC 55 aripiprazole Abilify 55 doxorubicin cyclophosphamide 55 EXPAREL TM 55 confirmatory Phase 3 55 Neovascular AMD 55 hyaluronidase enzyme 55 ADHF 55 nucleoside analog 55 virus HCV protease inhibitor 55 histologically confirmed 55 EOquin 55 Study ARIC 55 R#/MEM # 55 cEVR 55 docetaxel chemotherapy 55 Radiation Therapy Oncology 55 alpha interferons 55 ILUVIEN ® 55 Multicenter Randomized 55 Kepivance 55 TRA 2P 55 subcutaneously administered 55 citalopram hydrobromide 55 Clolar ® 55 masked placebo controlled 55 TELINTRA 55 LAF# 55 Index CDAI 55 chronic myocardial ischemia 55 oral calcitonin 55 tanespimycin 55 HeFH 55 CYPHER R Sirolimus eluting 55 pediatric acute lymphoblastic 55 QTc prolongation 55 lenalidomide Revlimid R 55 REG1 Anticoagulation System 55 INCB# [002] 55 chlorambucil 55 lispro 55 prasterone 55 biliary tract cancer 55 BEXXAR 55 liposome injection 55 Stenting Trial CREST 55 TAXUS Liberte Stent 55 invasive aspergillosis 55 goserelin 55 #mg/m# [002] 55 Complicated Skin 55 prospective nonrandomized 55 antiretroviral naïve 55 undergone radical prostatectomy 55 Dabigatran etexilate 55 TLK# 55 Tracleer R 55 sustained virologic response 55 Serious Adverse Events 55 DAVANAT 55 Placebo Controlled Trial 55 naïve HCV 55 randomized Phase IIb 55 Soriatane 55 radiolabeled TM# 55 Linagliptin 55 HGS ETR2 55 Hsp# Inhibitor 55 LB# [003] 55 Squamous 55 pomalidomide 55 MKC# MT 55 Cellegesic 55 Marketing Authorisation Application 55 Initiate Clinical Trial 55 CYT# potent vascular disrupting 55 oral salmon calcitonin 55 Navelbine 55 Randomized Clinical Trial 55 multicenter randomized clinical 55 bendamustine 55 Polyp Prevention Trial